Acetamoren vs MK-677 (Ibutamoren): 2026 Comparison — CAS, Mechanism, Half-Life & Research Applications

A research-grade head-to-head of Acetamoren (MK-777, CAS 950841-87-9) and MK-677 (Ibutamoren, free base CAS 159634-47-6 / mesylate CAS 159752-10-0) — covering chemistry, mechanism, half-life, appetite, blood-sugar effects, clinical status, SAR position, and how they sit alongside Capromorelin and Anamorelin in the broader non-peptide ghrelin receptor (GHS-R1a) agonist family.

1. MK-677 & Derivative Family Snapshot

The ghrelin receptor (GHS-R1a) is the most heavily explored non-peptide target for oral growth hormone (GH) and IGF-1 elevation. Within a single comparator table, the landscape looks like this:

2. CAS Numbers & Chemical Identity

Researchers frequently confuse the three CAS numbers because vendors list them interchangeably. They refer to two closely related entities:

• MK-677 free base (159634-47-6) is the neutral parent molecule — what every in vitro pharmacology paper describes.
• MK-677 mesylate (159752-10-0) is the same molecule as a methanesulfonate salt — preferred in catalogs and published PK work because of crystallinity and handling stability. The mesylate adds no pharmacologic novelty; dosimetry is normalized to free base equivalents.
• Acetamoren (950841-87-9) is a structurally modified analog sharing MK-677's spiropiperidine core, with an acetyl-methyl side-chain and a benzyloxymethyl substituent that distinguish it from MK-677.

3. Mechanism of Action — GHS-R1a Agonism Explained

Both MK-677 and Acetamoren are non-peptide agonists of the Growth Hormone Secretagogue Receptor 1a (GHS-R1a) — the seven-transmembrane Gα_q/11-coupled receptor for the endogenous orexigenic hormone ghrelin. The shared downstream cascade looks like this:

1. GHS-R1a binding at pituitary somatotrophs and hypothalamic neurons.
2. Gα_q / PLC / IP₃ / DAG signaling → intracellular Ca²⁺ release.
3. Pulsatile GH secretion from the anterior pituitary, amplified by GHRH synergism.
4. Hepatic IGF-1 elevation downstream of GH.
5. Appetite modulation at hypothalamic arcuate nucleus (NPY/AgRP neurons).

Why "non-peptide" matters

Peptide secretagogues (GHRP-2, GHRP-6, ipamorelin, hexarelin) need subcutaneous administration because gut proteases destroy them. MK-677 was deliberately designed as an oral small molecule — discovery criterion being oral activity in dogs at ≤0.125 mg/kg. Acetamoren inherits this pharmacokinetic advantage from the same chemical class.

What changes between MK-677 and Acetamoren

The receptor pocket is the same. The functional divergence is in:

• Half-life — MK-677 ≈ 24 h PD-effective; Acetamoren ≈ 8–10 h.
• Hypothalamic appetite signaling — MK-677 stimulates hunger (utility in cachexia); Acetamoren is reported to blunt it.
• Glycemic effect — MK-677 raises fasting glucose in clinical trials; Acetamoren's effect is not characterized in published literature.
• β-arrestin recruitment / receptor internalization bias — inferred by structural modification but not yet characterized peer-reviewed.

4. MK-677 (Ibutamoren) Deep Dive

MK-677 is the prototypal oral ghrelin-mimetic and the parent compound of the spiropiperidine series. Developed by Merck under the code L-163,191, it advanced to Phase II in elderly subjects with hip fracture, sarcopenia, and frailty — and was discontinued for commercial reasons. It remains the most clinically characterized member of the family.

Mechanism recap

Once-daily oral dosing with 25 mg restored 24-h GH pulsatility toward young-adult levels. The boost is from pulse-amplitude amplification, not from continuous release — i.e., MK-677 mimics physiological secretion rather than replacing it with constant exposure. IGF-1 rises into the 141–265 µg/L reference range over 4 weeks in elderly subjects.

Clinical highlights

• Sarcopenia trial (2-year): +1.1 kg fat-free mass vs. placebo in adults 60–81; no measurable improvement in strength or function.
• Hip-fracture trial: discontinued for non-efficacy reasons — narrowly missed functional end-points.
• Sleep-architecture signal: Stage III/IV slow-wave sleep increased; subjectively reports often call this the "cleanest" benefit.
• Appetite: robustly orexigenic; problematic in obesity populations but useful in catabolic states.
• Glucose: fasting glucose and HbA1c trend mildly upward in 2-year data — the recurrent reason cited for program-wide skepticism.

5. Acetamoren (MK-777) Deep Dive

Acetamoren is a structural analog of MK-677 designed to test appetite-attenuating substitutions on the spiropiperidine scaffold. Its IUPAC nomenclature already hints at the structural divergence:

Propanamide, 2-(acetylamino)-N-[(1R)-2-[1,2-dihydro-1-(methylsulfonyl)spiro[3H-indole-3,4'-piperidin]-1'-yl]-2-oxo-1-[(phenylmethoxy)methyl]ethyl]-2-methyl-

Key differentiators

• Reported appetite attenuation: Vendor and patent-derived notes describe an orexigenic reversal vs. MK-677 in rodent models, attributed to the acetyl-methyl substitution at the side-chain amide. The mechanism is uncharacterized.
• Shorter t_1/2 (8–10 h): A research setting in which cumulative GH exposure is preferred over pulsatile, peak-driven GH may want Acetamoren; researchers replicating MK-677-like 24-h coverage will not.
• Preclinical only: No IND, no human trial, no FDA or EMA evaluation, no WADA explicit listing (although structurally covered by S2.2.4).
• Identity caveat: PubChem does not list 950841-87-9 (it remains in CAS registry but unindexed in PubChem's curated bioactivity database). Identity must be confirmed by supplier COA + NMR + MS.

Where Acetamoren adds research value

1. Body-composition research where MK-677's orexigenic drive confounds feed-intake measurements.
2. Comparative GHS-R1a SAR — radioligand displacement, β-arrestin recruitment, Gα_q bias profiling in cell-free and cell-based assays.
3. Reference ligand for assays that need a "MK-677-like but partial / biased" tool.
4. Method-development work for spiropiperidine series LC-MS/MS analytical pipelines.

6. Half-Life, Pharmacokinetics & Dosing Implications

The functional consequence of half-life matters most when designing GH pulsatility experiments:

• MK-677's long t_1/2 preserves GH pulse amplitude but raises interpulse nadir — useful for "sustained IGF-1 elevation" experimental designs.
• Acetamoren's shorter t_1/2 may preserve a cleaner on/off exposure profile for assays that distinguish GH-axis activation from cumulative feedback.
• Capromorelin is the shortest-acting, used clinically for transient orexigenic boosts in veterinary settings.
• Anamorelin hits a middle ground — long enough for once-daily, short enough to allow daily wash-out.

7. Appetite, Glycemic & Metabolic Phenotypes

This is the most distinctive axis of difference between the two.

Clinical relevance of the appetite axis

MK-677's robust hunger stimulation makes it a useful positive control in cachexia research — but a confounding variable in obesity and dieting studies, where any feed-intake change must be uncoupled from the drug effect itself. Acetamoren, if the vendor-derived phenotype holds, is the more interesting candidate for body-composition paradigms that want GH-axis support without the orexigenic confound.

8. Clinical Status & Safety

9. Legality, WADA Status & Research Use

Regulatory status (human)

• MK-677 — never FDA-, EMA-, PMDA- or NMPA-approved for any human indication. Sold as a research chemical in the U.S. and similar jurisdictions.
• Acetamoren (MK-777) — same regulatory status. No clinical trial filings, no approved veterinary use, no INN assignment.
• Capromorelin — FDA-approved veterinary (Entyce® and Elura®). No human approval.
• Anamorelin — Approved as Adlumiz® in Japan (PMDA, 2021) for cancer cachexia in NSCLC / gastric / pancreatic / colorectal. Refused by EMA (2017) and not approved in the U.S.

WADA / anti-doping

• MK-677 is explicitly named on the World Anti-Doping Agency (WADA) Prohibited List, section S2 (Peptide Hormones, Growth Factors, Related Substances and Mimetics) — specifically S2.2 (Growth Hormone Releasing Factors and GHS-R1a agonists). Prohibited at all times, in and out of competition.
• Acetamoren is not individually named but is structurally covered by S2.2.4 as a GHS-R1a agonist. Athletes subject to anti-doping rules should treat it as prohibited.
• Capromorelin and Anamorelin are similarly captured under the broader category.

10. Comparison with Capromorelin, Anamorelin & the GHS Field

The two spiropiperidines discussed above live in a wider non-peptide GHS-R1a agonist field. Researchers running comparative work need to know where each sits:

How researchers typically choose

• Studying appetite stimulation / cachexia? MK-677, Capromorelin, or Anamorelin (depending on jurisdiction for the latter two).
• Studying appetite suppression with GH-axis activity? Acetamoren is the only candidate in this comparison.
• Need an SAR tool / reference comparator? Acetamoren and MK-0616 occupy that niche.
• Replicating published 24-h pulsatile IGF-1 curves? MK-677 — well-characterized baseline.

11. SAR Position: Where Acetamoren Sits in the Spiropiperidine Series

The Merck spiropiperidine series distinguishes itself by a spiro[3H-indole-3,4'-piperidine] core that delivers oral bioavailability, GHS-R1a affinity, and limited off-target binding. Modifications explored in the series include:

• C-1 sulfonyl substitution (methylsulfonyl in MK-677) — improves metabolic stability.
• Side-chain amide variations — drive selectivity for GH-axis vs. orexigenic / glycemic phenotypes.
• Hydrophobic α-substituents — tune receptor residence time.

Acetamoren is reported to modify the side-chain amide with an acetylamino + benzyloxymethyl substitution pattern. The structural shift is hypothesized to alter functional selectivity at GHS-R1a — i.e., bias toward G-protein vs. β-arrestin pathways, hypothalamic vs. pituitary selectivity, or receptor internalization kinetics — rather than wholesale receptor affinity. That is the reason Acetamoren is of interest to SAR researchers even with no published trials.

12. Researcher Decision Guide

Use this when designing a study and choosing which GHS-R1a agonist to anchor it with:

1. Define the readout first. GH pulse amplification? IGF-1 elevation? Appetite modulation? Body composition? Glycemic effect? Each favors a different compound.
2. Decide appetite tolerance. If paired-feeding or ad-libitum pair-matching is part of your design, MK-677's orexigenic effect will inflate your control arm. Switch to Acetamoren (caveat: less characterized).
3. Match scaffold to question. Spiropiperidine (MK-677, Acetamoren) for the oral GH-axis question, pyrazolinone-piperidine (Capromorelin) for transient orexigenic work, Anamorelin scaffold for cachexia / LBM benchmarks.
4. Verify jurisdiction. Capromorelin and Anamorelin are approved in limited jurisdictions; if you need a clinically validated benchmark, run both against MK-677 head-to-head.
5. Account for half-life. 24-h (MK-677) → once-daily; 8–10 h (Acetamoren) → twice-daily plausible; 7 h (Anamorelin) → once-daily. Match your sampling cadence accordingly.
6. QC upfront. Require COA with HPLC + NMR + MS. Cross-check CAS against lot-specific certificate. For Acetamoren especially, confirm identity before downstream work.

13. Product Quality, Storage & Sourcing Notes

NutraBiotech supplies Ibutamoren Mesylate (MK-677, CAS 159752-10-0) with full batch-specific COA including HPLC purity chromatogram, NMR, and MS data. Standard packs from 100 mg to 10 g+, with bulk and custom purity grades on request. Note: Acetamoren (MK-777, CAS 950841-87-9) is not currently a stock catalog item — contact our technical team for custom-synthesis availability or sourcing referral.

14. Frequently Asked Questions

15. Conclusion

MK-677 (Ibutamoren) and Acetamoren (MK-777) are two structurally related non-peptide GHS-R1a agonists occupying the same chemical scaffold but diverging on three research-critical axes: half-life (24 h vs. 8–10 h), appetite phenotype (orexigenic vs. reportedly attenuating), and evidence depth (Phase II clinical data vs. preclinical vendor-derived claims). Neither is approved for human use, and both fall under WADA section S2 in sport-related research.

For study planning: anchor MK-677 as your validated comparator, and treat Acetamoren as a complementary SAR / body-composition probe whose quantitative characteristics must be confirmed in-house before publication-grade work. Pair either with Capromorelin or Anamorelin if your research question crosses scaffold boundaries — and always verify identity at the COA level, especially for MK-777 where vendor catalogue entries have historically varied.